Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin
Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients,
The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diabetes (T2DM)
- Novartis is committed to optimizing patient management of T2DM to achieve better glycemic control and favorable long-term clinical outcomes
Basel, September 18, 2019 — Novartis today announced the key results from the Phase IV clinical study VERIFY evaluating the long-term efficacy and safety of early combination treatment strategy with metformin plus vildagliptin (dipeptidyl peptidase-4 [DPP-4] inhibitor) compared to the traditional stepwise approach with metformin as initial therapy followed by vildagliptin, added at the time of metformin failure,. The key study findings were presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting and published simultaneously in The Lancet.
VERIFY is a unique study designed to determine durability, over a pre-specified five-year follow-up of early use of combination therapy strategy with vildagliptin-metformin. The study was conducted across 254 centers in 34 countries and involved 2001 treatment-naïve diverse individuals recently diagnosed with T2DM (HbA1c between 6.5–7.5% [48–58 mmol/mol]),.
In the randomized, double-blind Phase IV study (ClinicalTrials.gov Identifier: NCT01528254), early combination therapy of vildagliptin (50 mg, twice daily) and metformin (individually, 1000–2000 mg, daily) met the primary endpoint with a statistically significant 49% reduction in the relative risk for time to initial treatment failure (HbA1c >= 7.0% twice, consecutively, 13 weeks apart), versus metformin alone (HR: 0.51, 95% CI [0.45, 0.58]; P<0·0001),.
The combination treatment strategy also showed a lower frequency of secondary failure when all patients were receiving combination therapy (HR: 0.74, 95% CI [0.63, 0.86]; P<0.0001). Furthermore, patients treated with early combination had consecutively lower HbA1c levels (below 6.0%, 6.5% or 7.0%) for 5 years versus those receiving combination therapy only after metformin monotherapy failure.
“The initial findings from the VERIFY study uniquely demonstrate that early intervention with a combination therapy strategy provides greater and durable long-term benefits for patients. The currently recommended initial monotherapy approach with later treatment intensification in type 2 diabetes management is now shown to be an inferior strategy,” said Professor David Matthews, EASD President and Emeritus Professor of Diabetic Medicine, University of Oxford, UK.
The overall safety and tolerability profile was similar between the treatment approaches, with no unexpected or new safety findings reported.
“Despite type 2 diabetes having become an epidemic with growing mortality and morbidity rates, there is a distinct lack of optimized management strategies at diagnosis that can induce durability and slow down disease progression,” said Marcia Kayath, Global Head Medical Affairs and Chief Medical Officer, Novartis Pharmaceuticals. “These promising results from the VERIFY study have the potential to improve patient outcomes and the way in which we treat type 2 diabetes in the future”.
Additional pre-defined secondary analyses of the VERIFY study results are ongoing and data will be disclosed over the coming months at international and local medical congresses and in scientific journals.
About vildagliptin/metformin combination (Eucreas® /Galvusmet®)
The combination of these two anti-diabetic agents with complementary mechanisms of action provides superior efficacy and allows patients to reach glycemic targets without increasing the risk of hypoglycemia, weight gain and other CV risk factors. Vildagliptin-metformin combination was the first single-pill dual therapy of a DPP-4 inhibitor with metformin approved in Japan and Europe. The vildagliptin and metformin dual therapy is used when the patient’s T2DM is insufficiently controlled by metformin monotherapy.
Vildagliptin is approved as an oral treatment for adults with T2DM in more than 120 countries, including the EU, Japan, Latin America and Asia-Pacific. Vildagliptin is approved for use as monotherapy, dual therapy in combination with metformin, sulfonylurea (SU) or a thiazolidinedione, as a triple oral therapy in combination with a SU and metformin or as an add-on to insulin (with or without metformin),,.
Vildagliptin is a selective and potent DPP-4 inhibitor that acts by preventing the usually rapid degradation of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which in turn, enhances the alpha- and ß-cell sensitivity to glucose and inhibits glucagon secretion, thereby improving glycemic control in T2DM,,,. Vildagliptin has been widely studied in randomized clinical trials but it also has an extensive pool of evidence in real world settings within diverse patient populations across the disease continuum.
Metformin hydrochloride is widely-used and is the recommended first-line therapy in patients with newly-diagnosed T2DM either immediately after diagnosis, or in those not able to achieve glycemic targets despite diet and other lifestyle interventions.
Despite its discovery already in 1922, the exact mode of action for metformin is not yet known. However, its effect in management of diabetes is through reduction of glucose output in the liver and secondarily, through increase of glucose uptake in the peripheral tissues. However, recent data suggests that some clinical activity may also arise from the synthesis and stimulation of intestinal release of incretin hormones,.
About VERIFY study,
The VERIFY study is a five-year, multi-center, randomized, double-blind Phase IV trial designed to assess the durability of glycemic control of a combination regimen strategy with vildagliptin and metformin compared with standard-of-care monotherapy approach with metformin initiated in treatment-naïve, diverse patients with recently diagnosed T2DM (HbA1c between 6.5-7.5% [48–58 mmol/mol]).
The study involved 2001 patients prescribed with stable dose of metformin (1000–2000 mg daily) 4 weeks prior to or during the trial and randomized (1:1) to receive additional vildagliptin 50 mg twice daily or placebo. Dose adjustment of metformin in both treatment arms was permitted during the first 4 weeks in the trial, to allow adjustment to a dose of up to 2000 mg/day or the maximum tolerable dose of at least 1000 mg/day post-randomization. If the initial treatment strategy failed to maintain an HbA1c level <7.0%, participants in the metformin monotherapy group were administered vildagliptin 50 mg twice daily in place of the placebo.
The primary endpoint was time to confirmed initial treatment failure, defined as HbA1c >=7% at two consecutive scheduled visits, 13 weeks apart. Secondary endpoints included rate of loss of glycemic control, HbA1c development over time, rate of loss in glycemic control in fasting plasma glucose, rate of loss of beta cell function from baseline to end of study, rate of change in insulin sensitivity from baseline to end of study, and rate of adverse events. Exploratory endpoints include adjudication of cardiovascular events and changes in glucose homeostasis (HOMA).
Diabetes mellitus is a condition characterized by increasing hyperglycemia due to defects in both insulin production and insulin sensitivity. The prevalence of diabetes has quadrupled in the past three decades with approximately 1 in 11 adults now having the disease worldwide, of these approximately 90% have T2DM. Additionally, factors such as glucose intolerance (pre-diabetes), underdiagnosed and/or delayed diagnosis of T2DM are causing a rapid increase in disease burden. This is especially seen in developing countries, which contributes to the continuously growing burden of diabetes. The International Diabetes Federation estimates that there is a new diagnosis every 6 seconds somewhere in the world.
After diagnosis, the majority of patients are unable to achieve and maintain the recommended glycemic control targets as defined by the guidelines. This universal lack of achievement of glycemic control is partly attributed to the current treatment paradigm involving sequential monotherapy, frequent early treatment failure and delayed therapy intensification leading to prolonged periods of sustained hyperglycemia. Combatting inertia in treatment intensification could also include a strategy of earlier and more comprehensive introduction combination therapy approach,.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
 Novartis. Data on file.
 NIH: ClinicalTrials.gov. VERIFY: A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT01528254. Accessed August 2019.
 Halimi S, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008: 4(3): 481-492.
 Novartis. Corporate Factsheet: Innovative Medicines. Available at: https://www.novartis.com/news/novartis-corporate-fact-sheet/innovative-medicines-en. Accessed August 2019.
 EMA Galvus SmpC. Available at: https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information_en.pdf. Accessed August 2019.
 Profit L, et al. Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2008: 3(1): 13-30.
 Pan CY & Wang XL. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag 2013: 9: 247-257.
 Garber AJ & Sharma MD. Update: vildagliptin for the treatment of Type 2 diabetes. Expert Opin Investig Drugs 2008: 17(1): 105-113.
 Stamataros G & Schneider SH. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2011: 12(12):1967-1973.
 Villhauer EB, et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J Med Chem 2003; 46(13): 2774-2789.
 Strain WD & Paldánius PM. Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. Eur Endocrinol 2017: 13(2): 62-67.
 Sanchez-Rangel E & Inzugghi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017: 60(9): 1586-1593.
 Rena G, et al. The mechanisms of action of metformin. Diabetologia 2017: 60(9): 1577-1585.
 American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013: 36(Suppl 1): S67-S74.
 Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018: 14(2): 88-98.
 International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. Available at: https://diabetesatlas.org/resources/2017-atlas.html. Accessed August 2019.
 Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Disease Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018 Dec; 41(12): 2669-2701
 Zinman, B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011: 124(Suppl 1): S19-S34.
# # #
Novartis Global External Communications
| Peter Zuest
Novartis Global External Communications
+41 61 324 6383 (direct)
+41 79 899 9812 (mobile)
Novartis US External Communications
+1 646 438 4335
| Meghan O’Donnell
Global Head Communications and Patient Advocacy, Cardio-Renal-Metabolism
+41 61 324 9136 (direct)
+41 79 797 9102 (mobile)
Head of Communications and Patient Advocacy, APMA Region
+65 67226010 (direct)
+65 9238 6791 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Pierre-Michel Bringer||+41 61 324 1065||Cory Twining|| +1 212 778 3258
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Golar LNG Partners LP: Q3 2019 results presentation21.10.2019 14:19:00 CEST | Press release
Golar LNG Partners LP 3rd Quarter 2019 results will be released before the NASDAQ opens on Tuesday November 26, 2019. In connection with this a webcast presentation will be held at 4:30 P.M (London Time) on Tuesday, November 26, 2019. The presentation will be available to download from the Investor Relations section at www.golarlngpartners.com This webcast will be immediately followed by a Q&A session. Participants will be able to join this webcast by dialling-in using the following details: a. Webcast Go to the Investors, Results Centre section at www.golarlngpartners.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have installed Windows Media Player, and you need to have a sound card on your computer. b. Teleconference Call-in numbers: International call +44 2071 928 000 UK Free call 0800 376 7922 US Toll +1 631 510 7495 USA Free call 866 966 1396 Norway Toll +47 23 96 02 64 Norway Free call 800 51874 The participants will be asked f
Rovio Entertainment Corp.: Capital Markets Day 2019 Agenda21.10.2019 14:16:00 CEST | Press release
Rovio Entertainment Corporation Press Release Oct. 21, 2019 Rovio Entertainment is organizing Capital Markets Day for analysts, institutional investors and financial media on Monday November 4th, 2019. Location: Kluuvikatu 4, 00100 Helsinki, Finland During the day Rovio’s CEO Kati Levoranta, together with members of Games leadership and other senior management, will present an overview on Rovio’s strategy, including a deep dive into the games portfolio and growth strategy. A short Q&A session is scheduled after each presentation and at the end of the day. Capital Markets Day 2019 agenda (all times in EET): 12:00-13:00 Registration & lunch 13:00-13:40 Rovio overview & strategy: winning in a dynamic growth market 13:40-13:55 Passionate, skillful teams and inspiring culture 13:55-15:10 Games - our unique approach to drive growth 15:10-15:25 Coffee Break 15:25-15:45 Angry Birds - building long-term franchise growth 15:45-16:00 Hatch - pioneering mobile game streaming 16:00-16:30 Financials
Norsk Hydro: REMINDER: Invitation - Hydro’s third quarter results 201921.10.2019 14:04:00 CEST | Press release
Hydro's third quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Wednesday October 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo and can also be seen on webcast. To attend the presentation in Oslo, please register by sending a mail to firstname.lastname@example.org. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). To join this event, please use the below “Click to Join” link 5-10 minutes prior to start time (choose “Click to Join” twice), where you will be asked to enter your phone number and registration details. The Event Confe
Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for tredje kvartal 201921.10.2019 14:04:00 CEST | Pressemelding
Hydros resultat for tredje kvartal 2019 blir offentliggjort onsdag 23. oktober 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Pål Kildemo. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til email@example.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start (velg “Click to Join“ to ganger), hvor du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og plas
Valmet to supply a coated board machine to Graphic Packaging International in the United States21.10.2019 14:00:00 CEST | Press release
Valmet Oyj’s press release on October 21, 2019 at 3:00 p.m. EET Valmet will supply a coated board machine for Graphic Packaging International’s (GPI) mill in Kalamazoo, Michigan, in the United States. With this investment in the latest coated board technology, GPI is committing to sustainable packaging with exceptional product quality and cost competitiveness for producing coated recycled board (CRB) grades. The start-up of the machine is scheduled for the first half of 2022. The order is included in Valmet's orders received of the third quarter 2019. The value of the order is not disclosed. “Valmet has offered us innovative yet proven technology to reach our high product quality targets. We have had a long and good cooperation with Valmet. Our relationship is based on mutual trust, which is very important in large projects like this one,” says Rusty Miller, Senior Vice President, Engineering and Technology, GPI. “Valmet has a very good relationship with Graphic Packaging International
Klövern säljer 42 fastigheter i Karlstad för 2 610 mkr21.10.2019 13:10:00 CEST | Pressemelding
Klövern har tecknat avtal om att avyttra hela sitt fastighetsbestånd i Karlstad, bestående av 42 fastigheter, för ett sammanlagt underliggande fastighetsvärde om 2 610 mkr. Fastigheternas uthyrningsbara yta uppgår till cirka 204 000 kvm och utgörs huvudsakligen av kontor samt lager/logistik. Hyresvärdet uppgår till 247 mkr och den ekonomiska uthyrningsgraden uppgår till 95 procent. Transaktionen görs i syfte att geografiskt renodla Klöverns fastighetsportfölj till färre orter. Frånträde är planerat till den 29 november 2019. Transaktionen omfattar följande fastigheter: Barkassen 7 Bälgen 11 Kanoten 10 Stolpen 1 Barkassen 9 Druvan 13 Kulingen 4 Stolpen 6 Björnen 13 Ekorren 11 Mercurius 3 Styrmannen 5 Björnen 7 Fjädern 14 Monitorn 9 Sågen 1 Blåsten 3 Fjädern 16 Passadvinden 3 Sågen 2 Blåsten 4 Freja 13 Pinassen 2 Sågen 9 Brisen 4 Grästegen 2 Regnvinden 1 Tornadon 2 Bromsen 1 Gångjärnet 2 Skepparen 15 Tången 15 Bromsen 6 Hammaren 21 Släggan 13 Ugnen 1 Bälgen 9 Herrhagen 1:10 Spärren 7 Vän